Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating clinical-trial disclosures, patent expiration timelines, or royalty obligations inside Pfizer’s massive SEC filings can feel like searching for a single molecule in a lab. Each 300-page Pfizer annual report 10-K simplified contains dozens of drug-pipeline tables, while every Pfizer quarterly earnings report 10-Q filing updates revenue by therapeutic area and COVID-19 vaccine demand. Add frequent 8-Ks announcing material study results and the picture grows increasingly complex for investors.
That’s where Stock Titan’s AI steps in. Our engine delivers real-time alerts and plain-English summaries the moment a new document hits EDGAR, turning Pfizer SEC filings explained simply into actionable insight. Need Pfizer insider trading Form 4 transactions? You’ll see executive stock trades within minutes, with context on trial milestones. Curious about Pfizer proxy statement executive compensation? Our AI highlights pay tied to oncology breakthroughs. Even Pfizer 8-K material events explained are broken down, so you understand why a Phase 3 success moves the stock.
Whether you’re comparing R&D spend across quarters, tracking Pfizer Form 4 insider transactions real-time, or performing Pfizer earnings report filing analysis, the platform ties each form to the questions professionals actually ask. Use the searchable dashboard to pinpoint:
- Segment revenue trends buried in 10-Qs
- Patent-cliff discussions inside the 10-K
- Pfizer executive stock transactions Form 4 around FDA decisions
Understanding Pfizer SEC documents with AI means no more manual page-turning—just concise insights on drug safety updates, collaboration economics, and global sales dynamics.
Pfizer Inc. director Mortimer J. Buckley reported a deferred compensation transaction involving phantom stock units tied to Pfizer common stock. On 12/31/2025, he acquired 1,506.024 phantom stock units, each representing one phantom share of common stock. These units reflect deferred director compensation, including dividend equivalents, and are designed to be settled in cash or Pfizer common stock at the director’s election after he retires from the Board of Directors. Following this transaction, Buckley beneficially owned a total of 15,078.063 phantom stock units, all held as a direct interest.
Pfizer Inc. director reports additional deferred compensation units
A Pfizer Inc. director reported acquiring 1,857.43 phantom stock units linked to Pfizer common stock on 12/31/2025. Each unit represents one phantom share of common stock. After this transaction, the director beneficially owns 149,314.146 derivative securities in the form of phantom stock units.
These units represent deferred director compensation, including dividend equivalents, that will be settled in either cash or Pfizer common stock at the director’s election after retirement from the Board of Directors.
Pfizer Inc director Shantanu Narayen reported acquiring 2,008.032 phantom stock units on Pfizer common stock as of 12/31/2025. Each unit represents one phantom share of common stock tied to deferred director compensation, including dividend equivalents.
These units are to be settled in cash or common stock at the director's election after retirement from the Board of Directors. Following this transaction, Narayen beneficially owned 183,164.359 derivative securities related to Pfizer common stock, recorded at a derivative security price of $24.9.
Pfizer Inc. director reports phantom stock unit grant tied to board compensation. On 12/31/2025, a reporting person serving as a Pfizer director acquired 1,556.225 phantom stock units linked to Pfizer common stock at a price of
Pfizer Inc. director reports additional deferred compensation in phantom stock units. On 12/31/2025, director James C. Smith acquired 1,807.229 phantom stock units tied to Pfizer common stock at a derivative security price of $24.9. After this transaction, he beneficially owned 166,119.84 derivative securities directly.
Each phantom stock unit represents one phantom share of Pfizer common stock. These units reflect deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at the director’s election after he retires from the Board of Directors. The filing reports an acquisition of compensation-linked units rather than an open-market stock sale.
Pfizer Inc. director compensation update: A Pfizer Inc. (PFE) director reported receiving 1,506.024 phantom stock units on 12/31/2025 as part of deferred director compensation. Each unit represents one phantom share of common stock, with the units to be settled in cash or common stock at the director's election following retirement from the Board of Directors. After this transaction, the director beneficially owned 25,349.741 phantom stock units, held in direct form.
Pfizer Inc. Chairman and CEO Albert Bourla, who also serves as a director of Pfizer Inc. (PFE), reported a routine change in his deferred compensation holdings as of 12/31/2025. The filing shows the acquisition of 24 Phantom Stock Units SSP, a type of derivative security that tracks Pfizer common stock.
Each phantom unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. These units are settled in cash after Bourla’s separation from service and may be moved into an alternative investment account at any time. Following this transaction, he beneficially owns 743,147 derivative securities related to these phantom stock units on a direct basis.
Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 23 phantom stock units linked to Pfizer common stock on 12/15/2025 under a deferred compensation plan.
Each unit represents one phantom share and is settled in cash after his separation from service. Following this transaction, Bourla beneficially owned 742,986 phantom stock units directly.
Pfizer Inc. furnished a regulatory disclosure stating that it issued a press release providing its full-year 2026 financial guidance and revising its full-year 2025 revenue guidance.
The company reaffirmed all other components of its full-year 2025 financial guidance in the same press release, which is attached as an exhibit to the disclosure.
Pfizer Inc. Chairman and CEO Albert Bourla reported an insider equity transaction involving company-linked deferred compensation. On 11/28/2025, he acquired 23 Phantom Stock Units SSP, each representing one phantom share of Pfizer common stock at a reference price of $25.74 per unit. Following this transaction, he beneficially owns 743,115 phantom stock units.
The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash after Bourla’s separation from service and may be moved by him into an alternative investment account at any time. The filing is made by one reporting person in his roles as both director and Chairman & CEO.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
